The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Yamada, Seiko Diane
PropertyValue
keywords Ovarian Cancer
overview Dr. Diane Yamada specializes in the diagnosis and treatment of gynecologic cancers. She is the Section Chief for Gynecologic Oncology at the University of Chicago. Her areas of interest include: Surgery for gynecologic malignancies including ovarian, uterine and cervical cancers, as well as minimally invasive surgery Prophylactic surgery for women at high risk for the development of hereditary ovarian and endometrial cancers Management of high grade uterine cancers Intraperitoneal chemotherapy Novel clinical trials Her research focuses on new treatments and drug development for ovarian and endometrial cancer, the regulation and radiologic imaging of ovarian cancer metastasis and the unique biology of aggressive uterine cancers. She conducts clinical trials targeting ovarian cancer as well as endometrial cancer. Dr. Yamada is an editorial reviewer for a number of academic medical journals, including the American Journal of Obstetrics and Gynecology, Gynecologic Oncology, and Cancer. She is also the author or co-author of numerous peer-reviewed publications, book chapters and reviews concerning gynecologic cancers. She holds national leadership positions on the gynecologic oncology board of the American Board of Obstetrics and Gynecology and she is President-Elect II for the Society of Gynecologic Oncology.
One or more keywords matched the following items that are connected to Yamada, Seiko Diane
Item TypeName
Concept Ovarian Neoplasms
Academic Article Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Academic Article Stage IIIC small cell carcinoma of the ovary: survival with conservative surgery and chemotherapy.
Academic Article The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma.
Academic Article c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.
Academic Article Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.
Academic Article c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.
Academic Article Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
Academic Article Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Academic Article Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.
Academic Article Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Academic Article {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.
Academic Article Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.
Academic Article Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.
Academic Article Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.
Academic Article Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.
Academic Article Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.
Academic Article Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.
Academic Article Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Academic Article Nanoscale Coordination Polymers Codeliver Chemotherapeutics and siRNAs to Eradicate Tumors of Cisplatin-Resistant Ovarian Cancer.
Academic Article Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.
Academic Article Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Academic Article Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.
Academic Article Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
Academic Article Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Academic Article Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Academic Article Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
Academic Article A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Academic Article Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group.
Academic Article Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.
Academic Article A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Academic Article Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Academic Article A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Academic Article Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Academic Article Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors.
Search Criteria
  • Ovarian Cancer